Favipiravir antiviral efficacy against SARS-CoV-2 in a hamster model
J.-S. Driouich, M. Cochin, G. Lingas, G. Moureau, F. Touret, P.-R. Petit, G. Piorkowski, K. Barthelemy, B. Coutard, J. Guedj, X. de Lamballerie, C. Solas, A. Nougairede
This study evaluates favipiravir's antiviral efficacy against SARS-CoV-2 in a Syrian hamster model, showing dose-dependent reduction of viral titers and disease symptoms.
bioRxiv · Jul 7, 2020Microbiology